Results for “biologic therapy”
Psoriasis
** Psoriasis is a chronic, non‑contagious autoimmune skin disorder that produces red, scaly plaques ranging from isolated patches to full‑body involvement. **CONTENT:** ## Overview Psoriasis is a long‑lasting autoimmune disease in which the immune system mistakenly accelerates the growth cycle of skin cells. Normally, epidermal cells mature over about a month; in psoriasis, this process is compressed to just three to four days, causing a buildup of immature cells that appear as **thick, silvery‑white scales** on a background of inflamed, reddish skin. The lesions can be **painful, itchy, and sometimes bleed** when scratched, and they may appear on the scalp, elbows, knees, lower back, and nails. While the condition is **non‑contagious**, its visibility can lead to significant psychosocial distress, affecting self‑esteem, work productivity, and quality of life. The disease exhibits a wide spectrum of severity. Some individuals experience **mild, localized plaques** that respond to over‑the‑counter moisturizers, whereas others develop **moderate to severe disease** that covers large body areas and may be associated with systemic inflammation. Psoriasis is also linked with comorbidities such as **psoriatic arthritis**, cardiovascular disease, metabolic syndrome, and depression. Because of these associations, psoriasis is increasingly viewed as a **systemic inflammatory disorder**, not merely a skin problem. A hallmark trigger is the **Koebner phenomenon**, where skin injury—such as a cut, scrape, or even a tattoo—induces new psoriatic plaques at the site of trauma. Other common triggers include infections (especially streptococcal throat infections), stress, smoking, alcohol, certain medications (e.g., beta‑blockers, lithium), and climate changes. Recognizing these factors helps patients and clinicians tailor lifestyle modifications alongside medical therapy. ## History/Background Descriptions of scaly skin eruptions date back to ancient Egypt (the Ebers Papyrus, c. 1550 BC) and classical Greek writings, where physicians noted “the disease of the king’s skin.” The term **psoriasis** derives from the Greek *psōr* (“itch”) and *‑iasis* (“condition”). In the 19th century, **Robert Willan** and **Robert Wood** classified skin diseases, distinguishing psoriasis from eczema. The autoimmune nature was not recognized until the mid‑20th century, when **M. M. Kelley** and colleagues demonstrated T‑cell involvement. The discovery of **TNF‑α** and interleukin‑17 pathways in the 1990s revolutionized treatment, leading to the first biologic agents (e.g., etanercept, 2003). The **Koebner phenomenon** was first described by **Heinrich Koebner** in 1876, emphasizing the role of skin injury in disease propagation. ## Key Information - **Epidemiology:** Affects ~2–3 % of the global population, with similar prevalence across genders and ethnicities. - **Pathophysiology:** Dysregulated **Th1/Th17** immune responses cause overproduction of cytokines (IL‑17, IL‑23, TNF‑α) that stimulate keratinocyte proliferation. - **Clinical Types:** Includes plaque psoriasis (most common), guttate, inverse, pustular, and erythrodermic forms. - **Diagnosis:** Primarily clinical; skin biopsy reserved for atypical presentations. The **Psoriasis Area and Severity Index (PASI)** quantifies disease burden. - **Treatment Spectrum:** - *Topical*: corticosteroids, vitamin D analogues, retinoids, coal tar. - *Phototherapy*: narrow‑band UVB, excimer laser. - *Systemic non‑biologic*: methotrexate, cyclosporine, acitretin. - *Biologic agents*: TNF inhibitors, IL‑12/23 inhibitors, IL‑17 inhibitors, IL‑23 inhibitors. - **Lifestyle Management:** Moisturizing, smoking cessation, weight control, stress reduction, and avoidance of known triggers. - **When to Seek Professional Care:** Immediate evaluation is warranted for sudden widespread redness (erythroderma), severe joint pain suggesting psoriatic arthritis, or if topical measures fail to control symptoms. Persistent lesions that bleed, develop infection, or cause significant emotional distress should also prompt a dermatologist visit. ## Significance Psoriasis is more than a cosmetic concern; it serves as a **model disease** for understanding autoimmunity and the skin‑immune axis. The development of targeted biologics has not only transformed psoriasis care but also paved the way for therapies in other inflammatory conditions, such as inflammatory bowel disease and rheumatoid arthritis. Economically, psoriasis imposes a substantial burden through direct medical costs and indirect losses from work absenteeism. Psychologically, the visible nature of lesions can lead to stigma, anxiety, and depression, underscoring the need for holistic management that includes mental‑health support. Ongoing research into the genetic basis (e.g., **HLA‑C*06:02**) and microbiome interactions promises to refine personalized treatment strategies, moving the field toward **precision dermatology**. **INFOBOX:** - Name: Psoriasis - Type: Chronic autoimmune skin disease - Date: First documented in ancient medical texts; modern classification established 19th century - Location: Worldwide; prevalence ~2–3 % of population - Known For: Red, scaly plaques; Koebner phenomenon; pioneering role in biologic therapy development **TAGS:** dermatology, autoimmune disease, skin disorders, chronic illness, biologic therapy, Koebner phenomenon, psoriatic arthritis, public health
Health & MedicineCrohns Disease
** Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract, causing abdominal pain, diarrhea, weight loss, and a range of extra‑intestinal complications. **CONTENT:** ## Overview Crohn’s disease belongs to the family of inflammatory bowel diseases (IBD), a group of disorders characterized by persistent inflammation of the gastrointestinal (GI) tract. Unlike ulcerative colitis, which is limited to the colon and rectum, **Crohn’s disease** may involve any segment from the mouth to the anus, most commonly the terminal ileum and colon. The inflammation is transmural, meaning it penetrates the full thickness of the bowel wall, which predisposes patients to strictures, fistulas, and perforation. Typical symptoms include **abdominal pain**, **persistent diarrhea**, **fever**, **abdominal distension**, and **unintended weight loss**. Because the disease is systemic, many patients also experience **fatigue**, **anemia**, **arthritis**, **eye inflammation (uveitis or episcleritis)**, and characteristic **skin lesions** such as **erythema nodosum** and **pyoderma gangrenosum**. The course of Crohn’s disease is highly variable; some individuals have mild, intermittent flares, while others endure severe, progressive disease that necessitates surgery. Diagnosis relies on a combination of clinical assessment, laboratory tests (e.g., C‑reactive protein, fecal calprotectin), endoscopic evaluation with biopsies, and cross‑sectional imaging (CT or MR enterography). Treatment is multidisciplinary, aiming to induce remission, maintain symptom‑free intervals, and prevent complications. Therapeutic options include **aminosalicylates**, **corticosteroids**, **immunomodulators** (azathioprine, methotrexate), **biologic agents** targeting tumor necrosis factor‑α (TNF‑α) or integrins, and, when necessary, surgical resection of diseased segments. Patients with Crohn’s disease should seek professional medical care promptly if they develop new or worsening abdominal pain, persistent high‑grade fever, signs of intestinal obstruction (vomiting, inability to pass gas or stool), or extra‑intestinal manifestations such as severe joint swelling or eye redness. Early intervention can reduce the risk of irreversible bowel damage and improve quality of life. ## History/Background The condition now known as Crohn’s disease was first described in a landmark 1932 paper by **Burrill B. Crohn**, **Leon G. Ginzburg**, and **Egon S. Oppenheimer** at Mount Sinai Hospital in New York. Their report detailed 14 patients with “regional ileitis,” distinguishing it from ulcerative colitis and other gastrointestinal disorders. The eponym “Crohn’s disease” gradually supplanted the original term, although the contributions of Ginzburg and Oppenheimer are increasingly recognized in modern histories. Throughout the mid‑20th century, the disease was considered rare, but epidemiologic studies in the 1970s and 1980s revealed a rising incidence in industrialized nations, suggesting environmental and lifestyle influences. The discovery of **genetic susceptibility loci**—most notably the **NOD2/CARD15** gene in the early 2000s—provided a molecular foothold for research. Subsequent genome‑wide association studies identified over 200 risk alleles, highlighting the complex interplay of genetics, the gut microbiome, and immune dysregulation. Therapeutic milestones include the introduction of **corticosteroids** in the 1950s, the approval of **azathioprine** for maintenance therapy in the 1970s, and the revolutionary launch of **infliximab**, the first anti‑TNF biologic, in 1998. These advances transformed Crohn’s disease from a condition often requiring extensive surgery to one that can be medically managed for many patients. ## Key Information - **Epidemiology:** Affects 3–20 per 100,000 individuals worldwide; peak onset between ages 15–35; slight female predominance in some regions. - **Pathophysiology:** Multifactorial—genetic predisposition (e.g., NOD2, IL23R), abnormal immune response to intestinal microbiota, and environmental triggers (smoking, diet, antibiotics). - **Clinical Features:** Abdominal pain (often RLQ), non‑bloody diarrhea, weight loss, low‑grade fever, perianal disease (fistulas, abscesses). Extra‑intestinal: anemia, erythema nodosum, pyoderma gangrenosum, arthritis, uveitis, primary sclerosing cholangitis. - **Complications:** Bowel obstruction from strictures, fistula formation, malabsorption, nutritional deficiencies, increased risk of **colorectal cancer** (especially after 8–10 years of disease) and **small‑bowel adenocarcinoma**. - **Diagnostic Tools:** Colonoscopy with ileal intubation, capsule endoscopy, MR/CT enterography, serologic markers (ASCA, pANCA), fecal calprotectin. - **Management:** Induction of remission (corticosteroids, budesonide, biologics), maintenance (immunomodulators, anti‑TNF agents, anti‑integrins, ustekinumab), nutritional therapy (enteral formulas, exclusive liquid diets), and surgery (strictureplasty, resection) when medically refractory. - **Monitoring:** Regular colonoscopic surveillance beginning 8–10 years after diagnosis, especially for colonic involvement, to detect dysplasia early. ## Significance Crohn’s disease exemplifies the challenges of chronic immune‑mediated disorders: it imposes a lifelong burden on patients, families, and health‑care systems. The disease’s unpredictable flares and potential for serious complications demand coordinated care involving gastroenterologists, surgeons, nutritionists, rheumatologists, dermatologists, and mental‑health professionals. Advances in biologic therapy have dramatically improved remission rates and reduced the need for surgery, yet many patients still experience refractory disease, underscoring the need for novel targets and personalized medicine. Beyond individual health, Crohn’s disease has spurred broader scientific insights into gut immunity, the microbiome, and the genetics of complex diseases. Research on Crohn’s has catalyzed the development of anti‑TNF agents now used across rheumatology, dermatology, and oncology. Public awareness and advocacy have also grown, leading to better insurance coverage for biologics and support for patient‑focused research. As the global incidence continues to rise, especially in newly industrialized nations, understanding and managing Crohn’s disease remains a public‑health priority. **INFOBOX:** - Name: Crohn’s disease (regional ileitis) - Type: Chronic inflammatory bowel disease (IBD) - Date: First described 1932 - Location: Can affect any part of the gastrointestinal tract (mouth to anus) - Known For: Transmural inflammation, extra‑intestinal manifestations, and increased cancer risk **TAGS:** inflammatory bowel disease, gastroenterology, autoimmune disease, chronic illness, biologic therapy, intestinal cancer, extra‑intestinal manifestations, patient education
Health & MedicineUlcerative Colitis
** Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes ulceration and inflammation of the colon and rectum, leading to abdominal pain, bloody diarrhea, and periods of remission and flare‑ups. **CONTENT:** ## Overview **Ulcerative colitis (UC)** is one of the two principal forms of inflammatory bowel disease (IBD), the other being Crohn’s disease. It is characterized by continuous inflammation that begins in the rectum and may extend proximally to involve part or all of the colon. The inflamed mucosa develops superficial ulcers, which bleed easily, producing the hallmark symptom of **hematochezia** (bright red blood in the stool). Patients typically experience crampy abdominal pain, urgency, and frequent watery or mushy stools that may contain mucus and blood. The disease follows a relapsing‑remitting course: periods of active inflammation (“flares”) alternate with intervals of relative quiescence (“remission”). Flares can be mild, with only a few loose stools per day, or severe, leading to massive bleeding, dehydration, and systemic signs such as fever, weight loss, and anemia. Extra‑intestinal manifestations are common, affecting the eyes (uveitis), joints (arthritis), skin (erythema nodosum), and liver (primary sclerosing cholangitis). Long‑standing UC increases the risk of **colorectal cancer**, especially when the disease involves the entire colon and has persisted for many years. Because UC is a chronic condition with no definitive cure, management focuses on controlling inflammation, maintaining remission, and monitoring for complications. Treatment options range from aminosalicylates and corticosteroids to immunomodulators, biologic agents, and, in refractory cases, surgical removal of the colon (colectomy). Patients should seek prompt medical evaluation if they notice new or worsening symptoms, especially severe abdominal pain, high‑fever, or a sudden increase in blood loss, as these may signal a life‑threatening complication such as **toxic megacolon**. ## History/Background The first clinical descriptions of ulcerative colitis date back to the 19th century. In 1859, British physician **Sir Samuel Wilks** reported a series of patients with “chronic ulcerative colitis,” distinguishing it from infectious dysentery. The term “ulcerative colitis” was coined by **Sir William Osler** in 1905, who emphasized the disease’s ulcerative nature and its confinement to the colon. Throughout the early 20th century, the condition was considered rare and often fatal, with limited therapeutic options. A major breakthrough occurred in the 1950s when **aminosalicylates** (e.g., sulfasalazine) were introduced, providing the first effective anti‑inflammatory medication for UC. The discovery of **corticosteroids** in the 1960s further improved flare control. In the 1990s, the advent of **immunosuppressive agents** (azathioprine, 6‑mercaptopurine) and later **biologic therapies** targeting tumor necrosis factor‑α (TNF‑α) and integrins revolutionized long‑term disease management. Surgical techniques also evolved, making total proctocolectomy with ileal pouch‑anal anastomosis (IPAA) a safe, continent‑preserving option for patients with refractory disease. Research into the genetic and environmental underpinnings of UC accelerated after the Human Genome Project, identifying susceptibility loci such as **HLA‑DRB1**, **IL23R**, and **NOD2**. These discoveries have paved the way for personalized medicine approaches that are still emerging in clinical practice. ## Key Information - **Epidemiology:** UC affects approximately 0.2–0.5 % of the population in North America and Europe, with a peak onset between ages 15–35 and a second smaller peak after age 50. - **Pathophysiology:** The disease results from an inappropriate immune response to intestinal microbiota in genetically predisposed individuals, leading to cytokine‑mediated mucosal injury. - **Diagnostic criteria:** Colonoscopy with biopsies remains the gold standard, revealing continuous mucosal ulceration, crypt architectural distortion, and inflammatory infiltrates. Laboratory tests may show anemia, elevated C‑reactive protein (CRP), and fecal calprotectin. - **Treatment hierarchy:** 1. **5‑ASA agents** (mesalamine, sulfasalazine) for mild‑to‑moderate disease. 2. **Corticosteroids** for acute flares. 3. **Immunomodulators** (azathioprine, methotrexate) for steroid‑sparing maintenance. 4. **Biologics** (infliximab, adalimumab, vedolizumab, ustekinumab) for moderate‑to‑severe or refractory disease. 5. **Surgery** (colectomy with IPAA) when medical therapy fails or complications arise. - **Complications:** Toxic megacolon, perforation, severe hemorrhage, primary sclerosing cholangitis, and increased colorectal cancer risk (surveillance colonoscopy every 1–3 years after 8–10 years of disease). - **Lifestyle considerations:** Diet modification, smoking cessation (smoking appears protective for UC but is harmful overall), stress management, and regular exercise can aid symptom control, though they do not replace medical therapy. **Important:** Anyone experiencing new, severe abdominal pain, persistent high‑grade fever, or a sudden surge in rectal bleeding should seek immediate medical attention, as these may indicate an emergency such as toxic megacolon or perforation. ## Significance Ulcerative colitis is a major public health concern because of its chronic nature, impact on quality of life, and association with serious complications. The disease imposes substantial economic costs related to healthcare utilization, lost productivity, and long‑term medication. Advances in biologic therapy have dramatically improved remission rates and reduced the need for colectomy, yet access to these treatments remains uneven worldwide. From a scientific perspective, UC serves as a model for studying mucosal immunology, host‑microbiome interactions, and the genetics of auto‑inflammatory disorders. Insights gained from UC research have informed therapeutic strategies for other immune‑mediated diseases, such as rheumatoid arthritis and psoriasis. Moreover, the emphasis on **surveillance colonoscopy** for cancer prevention underscores the broader principle of early detection in chronic inflammatory conditions. Understanding UC empowers patients, clinicians, and policymakers to implement timely interventions, promote research funding, and improve health outcomes for millions of individuals living with this challenging disease. **INFOBOX:** - Name: Ulcerative colitis - Type: Chronic inflammatory bowel disease (IBD) - Date: First described in 1859 (clinical description) - Location: Primarily affects the colon and rectum; worldwide distribution - Known For: Continuous colonic mucosal inflammation with ulceration and increased colorectal cancer risk **TAGS:** ulcerative colitis, inflammatory bowel disease, gastroenterology, autoimmune disease, colon cancer, biologic therapy, colonoscopy, extra‑intestinal manifestations